07:41:53 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-06-08 Bokslutskommuniké 2023
2023-03-01 Kvartalsrapport 2023-Q3
2022-12-01 Kvartalsrapport 2023-Q2
2022-10-03 Ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 Årsstämma 2023
2022-08-31 Kvartalsrapport 2023-Q1
2022-06-10 Bokslutskommuniké 2022
2022-03-02 Kvartalsrapport 2022-Q3
2021-12-02 Kvartalsrapport 2022-Q2
2021-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 Kvartalsrapport 2022-Q1
2021-05-31 Bokslutskommuniké 2021
2021-03-03 Kvartalsrapport 2021-Q3
2020-12-02 Kvartalsrapport 2021-Q2
2020-09-30 Årsstämma 2021
2020-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 Kvartalsrapport 2021-Q1
2020-06-08 Bokslutskommuniké 2020
2020-04-20 Extra Bolagsstämma 2020
2020-03-02 Kvartalsrapport 2020-Q3
2019-12-02 Kvartalsrapport 2020-Q2
2019-09-30 Årsstämma 2020
2019-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 Kvartalsrapport 2020-Q1
2019-06-10 Bokslutskommuniké 2019
2019-03-04 Kvartalsrapport 2019-Q3
2018-12-17 Kvartalsrapport 2019-Q2
2018-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 Kvartalsrapport 2019-Q1
2018-09-24 Årsstämma 2019
2018-06-25 Bokslutskommuniké 2018
2018-03-26 Kvartalsrapport 2018-Q3
2017-12-18 Kvartalsrapport 2018-Q2
2017-09-25 Kvartalsrapport 2018-Q1
2017-09-25 Årsstämma 2018
2017-06-30 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamma inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2022-10-11 11:50:13

Mölndal, Sweden, October 11[th], 2022 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has received a patent approval in the US describing components and design features of the OPRA[TM] Implant System, including elements that were implemented in 2017 and later were granted a PMA approval in late 2020. The patent period extends until 2044.

Integrum develops the OPRA[TM ]Implant System, a revolutionary implant technology based on the company's deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality of life.

The current patent includes claims covering the system as a whole, including the anchoring solution for attaching a prosthesis into the human body as well as the abutment and the abutment screw. These claims extend beyond transfemoral applications, which currently make up the majority of treatment cases, to include treatment in other types of long bone prosthetic applications, such as the upper arm or lower leg.

Further, the claims cover design features for the connection between the abutment and the fixture, allowing a pathway for communication of physical and biophysical signals between inside and outside of the human body. Such design aspects are of vital importance to, for example, the e-OPRA[TM] Implant System - Integrum's state-of-the-art mind-controlled robotic prosthesis.

The patent grants Integrum exclusivity to OPRA[TM] Implant System ranging from October 11[th] ,2022, until 2044 and is of vital importance to the continued commercial success on the world's largest medical technology market.

"We are encouraged by this further recognition of Integrum as an innovative leader developing state-of-the-art products within osseointegration. We are currently working ambitiously to implement OPRA[TM] Implant System as the new standard of care in amputation treatment, and the new patent offers broad protection for a long time ahead", comments Rickard Brånemark, CEO of Integrum.